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factor in advanced childhood myelodysplastic syndrome
Abstract
To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic
syndrome, overall survival of 192 children prospectively enrolled in European Working Group of
Myelodysplastic Syndrome in Childhood studies was evaluated with regard to karyotypic complexity.
Structurally complex constitutes a new definition of complex karyotype characterized by more than or
equal to 3 chromosomal aberrations, including at least one structural aberration. Five-year overall
survival in patients with more than or equal to 3 clonal aberrations, which were not structurally
complex, did not differ from that observed in patients with normal karyotype. Cox regression analysis
revealed the presence of a monosomal and structurally complex karyotype to be strongly associated with
poor prognosis (hazard ratio = 4.6, P < .01). Notably, a structurally complex karyotype without a
monosomy was associated with a very short 2-year overall survival probability of only 14% (hazard
ratio = 14.5; P < .01). The presence of a structurally complex karyotype was the strongest independent
prognostic marker predicting poor outcome in children with advanced myelodysplastic syndrome.
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CLINICAL TRIALS AND OBSERVATIONS
Brief report
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To identify cytogenetic risk factors pre-
dicting outcome in children with ad-
vanced myelodysplastic syndrome, over-
all survival of 192 children prospectively
enrolled in European Working Group of
Myelodysplastic Syndrome in Childhood
studies was evaluated with regard to
karyotypic complexity. Structurally com-
plex constitutes a new definition of com-
plex karyotype characterized by more than
or equal to 3 chromosomal aberrations,
including at least one structural aberra-
tion. Five-year overall survival in patients
with more than or equal to 3 clonal aber-
rations, which were not structurally com-
plex, did not differ from that observed
in patients with normal karyotype. Cox
regression analysis revealed the pres-
ence of a monosomal and structurally
complex karyotype to be strongly asso-
ciated with poor prognosis (hazard
ratio  4.6, P < .01). Notably, a structur-
ally complex karyotype without a mono-
somy was associated with a very short
2-year overall survival probability of only
14% (hazard ratio  14.5; P < .01). The
presence of a structurally complex
karyotype was the strongest indepen-
dent prognostic marker predicting poor
outcome in children with advanced my-
elodysplastic syndrome. (Blood. 2010;
116(19):3766-3769)
Introduction
Karyotypic complexity has been reported to be associated with a
poor prognosis in myeloid neoplasia.1-3 However, the definition of
a complex karyotype remains a matter of debate. Most studies
defined a complex karyotype as more than or equal to 3 indepen-
dent abnormalities.2,4-6 In the Medical Research Council Acute
Myeloid Leukemia 10 (MRC AML10) trial, more than or equal to
5 independent abnormalities were required3 because acute myeloid
leukemia (AML) patients with more than or equal to 5 abnormali-
ties had a significantly worse 5-year overall survival (OS) than
those with 3 or 4 abnormalities.1 Increased numbers of chromo-
somal abnormalities were also found to adversely influence median
survival in adult myelodysplastic syndrome (MDS) patients.7
Breems et al recently investigated the prognostic value of different
cytogenetic components of a complex karyotype in adult AML and
identified a monosomal karyotype (ie, either one single autosomal
monosomy in the presence of at least one structural aberration or at
least 2 distinct autosomal monosomies) as a highly unfavorable
risk category.8 To better stratify children with advanced MDS, we
evaluated the outcome in 192 children prospectively diagnosed and
treated within the studies of the European Working Group of MDS
in Childhood (EWOG-MDS) related to karyotypic complexity.
This study is registered at www.clinicaltrials.gov as #NCT00047268
and #NCT00662090.
Methods
All patients younger than 18 years with adequate cytogenetic studies and
advanced MDS (ie, refractory anemia with excess blasts or refractory
anemia with excess blasts in transformation),9,10 enrolled in studies
EWOG-MDS 98 (www.clinicaltrials.gov; #NCT00047268) or EWOG-
MDS 2006 (#NCT00662090) between July 1, 1998 and June 30, 2008 were
included in this analysis. In both studies, therapy recommendation con-
sisted of upfront hematopoietic stem cell transplantation (HSCT). Institu-
tional review board approval was obtained for both EWOG studies from all
participating institutions.
Cytogenetic analyses of bone marrow cells were performed according
to standard procedures.11 Karyotypes were described according to Inter-
national System for Human Cytogenetic Nomenclature 2009.12 At least
10 metaphases were analyzed (supplemental Tables 1-3, available on the
Blood Web site; see the Supplemental Materials link at the top of the online
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article). Cytogenetic findings were centrally reviewed (G.G., H.B.B., D.B.).
All cytogenetic studies were performed before administration of MDS-
specific therapy. A structurally complex karyotype was defined as more than
or equal to 3 chromosomal aberrations, including at least one structural
aberration (supplemental Table 4). Because we have never been able to
detect differences in OS between patients with monosomy 7 as sole
aberration, monsomy 7 and clonal evolution, or monosomy 7 and other
aberrations (excluding those with structurally complex karyotypes, supple-
mental Table 5), we grouped all patients with monosomy 7. Thus, the
monosomy 7 group included those with clonal evolution and additional
aberrations.
The Kaplan-Meier method was used to estimate OS probabilities.13 The
log-rank test was used to compare survival between subgroups. For
multivariate analysis, the Cox proportional hazard regression model was
used.14 HSCT was included as a time-dependent covariate in the model.
The different definitions of complex karyotype coded in a variable with
k-categories were transformed into k-1 dummy variables and added to the
model.15 All P values were 2-sided, and values less than .05 were
considered statistically significant. Statistical analysis was performed using
SPSS for Windows Version 15.0.1.
Results and discussion
Cytogenetic data from 192 patients with refractory anemia with
excess blasts and refractory anemia with excess blasts in transfor-
mation were analyzed (supplemental Table 3). HSCT was per-
formed in 143 patients (74%) resulting in a probability of OS at
5 years of 0.58 for all children with primary MDS and 0.47 for
those with secondary MDS (P  .09). Here we analyze the
prognostic significance of a novel simple definition of a complex
karyotype termed structurally complex (ie, 3 chromosomal
aberrations, including at least one structural aberration), intro-
duced for the following reasons: The most frequent chromosomal
aberrations of highly complex clones are deletions, unbalanced
translocations and dicentric chromosomes. Monosomies are also
often noted in karyotypes with multiple aberrations. However, it
may be difficult to be certain that a particular chromosome is lost.
Using more advanced molecular cytogenetic techniques, such as
Figure 1. Probabilities of 5-year survival according to cytogenetic stratifications. (A) Probability of 5-year OS for children with advanced primary or secondary MDS
according to cytogenetic stratification. Traditionally, a complex karyotype is defined by the presence of more than or equal to 3 or more than or equal to 5 aberrations.
Structurally complex karyotype is defined by at least 3 chromosomal aberrations, including at least one structural aberration, excluding those with clonal evolution of monosomy
7. Karyotypes were grouped in the following hierarchical order: more than or equal to 5 aberrations, 3 or 4 aberrations, structurally complex, monosomy 7 (with or without other
aberrations), normal karyotype, other karyotypes. (B) The probability of 5-year OS for children with: advanced primary or secondary MDS with structurally complex karyotype;
monosomal karyotype with at least one autosomal monosomy and one or more structural aberrations that did not fulfill the criteria of a structurally complex karoytpe
(“monosomal karyotype only”); monosomy 7 with or without additional aberrations, including clonal evolution of monosomy 7; normal karyotype; other karyotypes. (C) The
probability of 5-year OS for patients according to cytogenetic subgroup. Patients classified as monosomal karyotype only in panel B are now included in the group of monosomy
7 (with or without additional aberrations) or other karyotypes. (D) Probability of 5-year event-free survival for patients who received allogeneic HSCT (N  143).
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fluorescence in situ hybridization or array comparative genomic
hybridization, it often transpires that parts of “missing” chromo-
somes are involved in structural aberrations. In addition, structural
aberrations, such as deletion 5q, deletion 7q, and deletion 17p, or
aberrations, involving 3q, 11q, and 12p, are known to be associated
with a poor prognosis in AML and MDS.1,16,17
The number of patients identified by the traditional definition of
complex karyotype with more than or equal to 3 clonal aberrations,
complex karyotype with more than or equal to 5 clonal aberrations,
and structurally complex karyotype was 35 (18%), 19 (10%), and
28 (15%), respectively (supplemental Table 6). With the exception
of one patient, all patients with more than or equal to 5 clonal
aberrations were also recognized as structurally complex. Seven
patients with more than or equal to 3 clonal aberrations did not
fulfill the criteria of a structurally complex karyotype, resulting
from the absence of structural aberrations by standard cytogenetics.
Notably, 5 of these 7 patients are still alive at a median time of
6.9 years (range, 0.2-8.7 years) after diagnosis (Figure 1A).
Children with a structurally complex karyotype had a highly
unfavorable prognosis with a 2-year OS probability of 0.14 (range,
0.00-0.30; Figure 1B-C). The group of patients with a structurally
complex karyotype given HSCT had a significantly shorter event-
free survival (P  .01, Figure 1D) and OS (data not shown) than
children with other karyotypes resulting from a higher risk of
relapse after HSCT (0.48, range, 0.27-0.82 vs 0.28, 0.20-0.38,
P  .01). Whether novel therapy approaches before HSCT can
improve outcome after HSCT for children with structurally com-
plex karyotype remains to be determined.
Recently, patients with a monosomal karyotype were shown to
have a dismal prognosis.8 Here, a monosomal karyotype with at
least 2 autosomal monosomies was seen in 12 (6%) patients. Of
these 12 patients, all but one were included in the group with
structurally complex karyotype, whereas 17 of the 28 patients with
a structurally complex karyotype did not have 2 autosomal
monosomies. A monosomal karyotype with at least one autosomal
monosomy and one/or more structural aberrations was noted in
30 (16%) patients (supplemental Tables 7, 8). In summary, of the
30 monosomal karyotypes with at least one autosomal monosomy
and one or more structural aberrations, 19 fulfilled the definition of
a structurally complex karyotype. The 5-year OS of these patients
was significantly worse than that of the 11 monosomal patients
not coded as structurally complex (P  .01, Figure 1B). Thus, a
monosomal karyotype in childhood MDS identifies a group of
patients with a heterogeneous prognosis. In contrast, using the new
definition of a structurally complex karyotype, only children with a
highly unfavorable prognosis were identified.
The Cox model included demographic data (gender, age) and all
variables with a P  .1 in the univariate analysis. Age more than or
equal to 15 years was associated with an increased risk of patient
death (hazard ratio [HR] 1.7; P  .05, Table 1). HSCT improved
the outcome significantly (HR 0.4; P  .05). Statistical analysis
of the different definitions of complex karyotype had to take into
account that some patients fulfilled the criteria of more than one
definition. The presence of a monosomal karyotype was an
independent adverse prognostic factor only when it also fulfilled
the criteria of a structurally complex karyotype (HR 4.6; P .01,
Table 1). In contrast, a monosomal karyotype that did not fulfill the
criteria of a structurally complex karyotype (supplemental Table 8,
“monosomal karyotype only”) did not identify a group with an
inferior outcome. Notably, a structurally complex karyotype with-
out a monosomy (“structurally complex only”) was associated with
a poor probability of OS (HR 14.4; P  .01). This held for both
primary and secondary MDS (primary MDS, n 9; secondary
MDS, n 19; supplemental Table 6). Thus, the presence of a
structurally complex karyotype was a better predictor of a very
unfavorable prognosis in children with MDS than the presence of
more than or equal to 3 clonal aberrations or a monosomal
karyotype.
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